The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials
Obesity is a growing health crisis that places a significant burden on health-care systems worldwide, with an estimated global prevalence of 2.1 billion people suffering from overweight or obesity in...
Conclusion: GLP-1 analogues are effective obesity management therapy that could decrease food intake and eventually reduce weight by suppressing appetite, reducing hunger, decreasing gastric emptying, and altering food preferences and taste. However, high-quality, long-term, large sample size studies are crucial to examine the efficacy and...
Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy
Source : https://www.sciencedirect.com/science/article/abs/pii/S0952818023000417?via=ihub
Semaglutide, a GLP-1 agonist, has been associated with delayed gastric emptying. * 5.1% of patients not using semaglutide had increased residual gastric content (RGC). * 24.2% of patients taking semaglutide...
Conclusions: Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.
A Randomized Controlled Trial of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients with Elevated Risk for Cardiovascular Disease: Rationale and Design of the BE ACTIVE Study
Source : https://www.sciencedirect.com/science/article/abs/pii/S0002870323000480?via=ihub
Available online 2 March 2023 Author links open overlay panel 1 2 3 4 5 , , 1 4 5 , , , 3 7 , , 1 3 7...
Conclusions: BE ACTIVE is a virtual, pragmatic randomized clinical trial powered to demonstrate whether gamification, financial incentives, or both are superior to attention control in increasing physical activity. Its results will have important implications for strategies to promote physical activity in patients with or at risk for ASCVD,...
Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36869853/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: These results support the benefits of semaglutide in a real-world setting in adults with T2D in France demonstrating a significant reduction in HbA1c and body weight.
Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology
Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1125753/full
Background: Several clinical trials have demonstrated that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) reduce the incidence of non-fatal myocardial infarction (MI) in patients with type 2 diabetes mellitus (T2DM). However,...
Conclusion: GLP-1RAs exert multi-dimensional effects on reducing the occurrence of MI in T2DM patients by interfering with targets, biological processes, and cellular signaling pathways related to atheromatous plaque, myocardial remodeling, and thrombosis.